Ingevity Corp.

As of October 24, 2025, Ingevity Corp. has a bullish trend supported by daily moving averages and Bollinger Bands, despite a mildly bearish MACD signal on the weekly timeframe, and it has significantly outperformed the S&P 500 with a 77.49% return over the past year compared to 16.90%.

As of October 24, 2025, Ingevity Corp. shows a bullish trend supported by daily moving averages and Bollinger Bands, though the weekly MACD presents a mildly bearish signal, indicating mixed signals overall.

As of October 24, 2025, Ingevity Corp. shows a bullish technical trend with strong daily moving averages and performance, despite some mixed signals from the MACD, while significantly outperforming the S&P 500 over the past year.

As of August 5, 2025, Ingevity Corp. shows a bullish technical trend with strong momentum, having outperformed the S&P 500 year-to-date and over the past year, despite some mixed signals from longer-term indicators.

As of February 21, 2024, Ingevity Corp. is considered risky and overvalued with a P/E ratio of 7 compared to the peer average of 11.75, and despite a strong year-to-date return, its long-term performance has significantly lagged behind the S&P 500.

As of February 21, 2024, Ingevity Corp. is considered a risky investment despite its undervalued metrics, including a low P/E ratio of 7 and a high ROE of 97.71%, especially when compared to peers like Avient Corp. and Innospec, Inc., although it has underperformed against the S&P 500 over the past year.

As of June 13, 2025, Ingevity Corp.'s technical trend has shifted to sideways, with mixed indicators showing a weak overall trend and indecision in the market.

As of March 2022, the management team of Ingevity Corp. includes Chairman Richard Kelson, CEO John Fortson, Lead Independent Director Frederick Lynch, and several Independent Directors: Jean Blackwell, Luis Fernandez-Moreno, J. Michael Fitzpatrick, and Diane Gulyas. They oversee the company's strategic direction and operations.

Ingevity Corporation manufactures specialty chemicals and high-performance carbon materials, with recent net sales of $284 million and a market cap of $1.66 billion. Key financial metrics include a P/E ratio of 7.00 and a return on equity of 97.71%.

As of Jun 18, Ingevity Corp. has a market capitalization of 1,664.35 million, categorizing it as a Small Cap company, with net sales of 1,350.20 million and a net profit loss of 353.80 million reported for the latest four quarters. The balance sheet shows shareholder's funds of 195.20 million and total assets of 2,022.60 million.